JP2020533382A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533382A5 JP2020533382A5 JP2020515147A JP2020515147A JP2020533382A5 JP 2020533382 A5 JP2020533382 A5 JP 2020533382A5 JP 2020515147 A JP2020515147 A JP 2020515147A JP 2020515147 A JP2020515147 A JP 2020515147A JP 2020533382 A5 JP2020533382 A5 JP 2020533382A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- sequence identity
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023120187A JP2023139178A (ja) | 2017-09-14 | 2023-07-24 | 癌の組合せ治療 |
| JP2025093685A JP2025131722A (ja) | 2017-09-14 | 2025-06-04 | 癌の組合せ治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558575P | 2017-09-14 | 2017-09-14 | |
| US62/558,575 | 2017-09-14 | ||
| PCT/IB2018/056967 WO2019053611A1 (en) | 2017-09-14 | 2018-09-12 | POLY THERAPY FOR THE TREATMENT OF CANCER |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023120187A Division JP2023139178A (ja) | 2017-09-14 | 2023-07-24 | 癌の組合せ治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020533382A JP2020533382A (ja) | 2020-11-19 |
| JP2020533382A5 true JP2020533382A5 (https=) | 2021-10-21 |
Family
ID=63713944
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515147A Pending JP2020533382A (ja) | 2017-09-14 | 2018-09-12 | 癌の組合せ治療 |
| JP2023120187A Pending JP2023139178A (ja) | 2017-09-14 | 2023-07-24 | 癌の組合せ治療 |
| JP2025093685A Pending JP2025131722A (ja) | 2017-09-14 | 2025-06-04 | 癌の組合せ治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023120187A Pending JP2023139178A (ja) | 2017-09-14 | 2023-07-24 | 癌の組合せ治療 |
| JP2025093685A Pending JP2025131722A (ja) | 2017-09-14 | 2025-06-04 | 癌の組合せ治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11401334B2 (https=) |
| EP (1) | EP3694878A1 (https=) |
| JP (3) | JP2020533382A (https=) |
| CN (1) | CN111108125A (https=) |
| BR (1) | BR112020005079A2 (https=) |
| CA (1) | CA3075714A1 (https=) |
| WO (1) | WO2019053611A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119264211A (zh) | 2018-08-27 | 2025-01-07 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| SG11202113008YA (en) * | 2019-05-31 | 2021-12-30 | Medimmune Llc | Combination therapy |
| WO2021136308A1 (en) | 2020-01-03 | 2021-07-08 | Biosion Inc. | Antibodies binding bcma and uses thereof |
| US20240181073A1 (en) * | 2021-03-03 | 2024-06-06 | Sorrento Therapeutics, Inc. | Antibody-Drug Conjugates Comprising an Anti-BCMA Antibody |
| US20260053939A1 (en) * | 2022-01-25 | 2026-02-26 | Glaxosmithkline Intellectual Property Development Limited | Combination Therapy for Cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| ES2571219T3 (es) | 2001-01-25 | 2024-09-23 | The United States Of America Represented By The Sec Dep Of Health And Human Services | Formulación de compuestos de ácido borónico |
| US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
| US8129346B2 (en) | 2004-04-15 | 2012-03-06 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
| PT2260835E (pt) | 2004-12-07 | 2013-05-28 | Onyx Therapeutics Inc | Composição para inibição do proteassoma |
| MY171061A (en) | 2005-11-09 | 2019-09-24 | Onyx Therapeutics Inc | Compounds for enzyme inhibition |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
| EP2730579A1 (en) | 2008-06-17 | 2014-05-14 | Millennium Pharmaceuticals, Inc. | Boronate ester compounds and pharmaceutical compositions thereof |
| TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
| KR101972446B1 (ko) * | 2011-05-27 | 2019-04-25 | 글락소 그룹 리미티드 | Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질 |
| UA112434C2 (uk) * | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| RU2615385C2 (ru) | 2012-02-28 | 2017-04-04 | Сидекс Фармасьютикалс, Инк. | Композиции алкилированного циклодекстрина и способы их получения и применения |
| RU2766608C2 (ru) | 2012-04-11 | 2022-03-15 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
| UY35091A (es) | 2012-10-24 | 2014-05-30 | Onyx Therapeutics Inc | Formulaciones de liberacion modificada para oprozomib |
| WO2014068079A1 (en) | 2012-11-01 | 2014-05-08 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| WO2014122143A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | Method for the selection of antibodies against bcma |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| GB201317928D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| EP3131927B8 (en) | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| JP6285274B2 (ja) | 2014-04-28 | 2018-02-28 | 株式会社ブリヂストン | バイアスタイヤ及びその製造方法 |
| GB201409471D0 (en) * | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| ES2878449T3 (es) | 2014-07-24 | 2021-11-18 | 2Seventy Bio Inc | Receptores antigénicos quiméricos de BCMA |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| MX382904B (es) * | 2014-08-05 | 2025-03-13 | Exelixis Inc | Combinaciones de fármacos para tratar mieloma múltiple. |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| MY191537A (en) | 2014-12-05 | 2022-06-30 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| SI3226897T1 (sl) | 2014-12-05 | 2021-08-31 | Memorial Sloan Kettering Cancer Center | Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe |
| TWI703159B (zh) * | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| SI3331910T1 (sl) | 2015-08-03 | 2020-07-31 | Engmab Sarl | Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA) |
| EP3147954A1 (en) | 2015-09-22 | 2017-03-29 | Nokia Technologies Oy | Photodetector with conductive channel made from two dimensional material and its manufacturing method |
| JP2019505476A (ja) * | 2015-12-01 | 2019-02-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 組合せ処置およびその方法 |
-
2018
- 2018-09-12 JP JP2020515147A patent/JP2020533382A/ja active Pending
- 2018-09-12 CA CA3075714A patent/CA3075714A1/en active Pending
- 2018-09-12 BR BR112020005079-2A patent/BR112020005079A2/pt unknown
- 2018-09-12 CN CN201880060081.0A patent/CN111108125A/zh active Pending
- 2018-09-12 WO PCT/IB2018/056967 patent/WO2019053611A1/en not_active Ceased
- 2018-09-12 EP EP18779780.8A patent/EP3694878A1/en active Pending
- 2018-09-12 US US16/646,836 patent/US11401334B2/en active Active
-
2022
- 2022-06-22 US US17/846,950 patent/US12234293B2/en active Active
-
2023
- 2023-07-24 JP JP2023120187A patent/JP2023139178A/ja active Pending
-
2025
- 2025-01-22 US US19/033,609 patent/US20250163172A1/en active Pending
- 2025-06-04 JP JP2025093685A patent/JP2025131722A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533382A5 (https=) | ||
| JP2020500538A5 (https=) | ||
| JP2024167313A5 (https=) | ||
| JP2017528476A5 (https=) | ||
| JP2021529557A5 (https=) | ||
| IL257281A (en) | Anti-pd-1 antibodies and methods of using them | |
| MX2025004236A (es) | Anticuerpo anti proteina reguladora de se?ales alfa (sirpalfana) | |
| JP2020508303A5 (https=) | ||
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| JP2018507220A5 (https=) | ||
| JP2015514110A5 (https=) | ||
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| NZ603972A (en) | Anti-fgfr2 antibodies | |
| JP2021501579A5 (https=) | ||
| FI3740504T3 (fi) | CD70-yhdistelmähoito | |
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| JP2020533383A5 (https=) | ||
| JP2022525377A5 (https=) | ||
| JP2017534577A5 (https=) | ||
| JP2018535650A5 (https=) | ||
| JP2019504032A5 (https=) | ||
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| JP2022516351A5 (https=) | ||
| RU2021103288A (ru) | МОЛЕКУЛЫ СО СПЕЦИФИЧНОСТЬЮ В ОТНОШЕНИИ CD79 и CD22 | |
| JP2011528902A5 (https=) |